IRCT2017020432236N5已完成2 期
Evaluation of efficacy and safety of aripiprazole in treatment of Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) induced sexual dysfunction: a randomized double blind controlled trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 50 years（—）
- 性别
- All
入选标准
- •Outpatients with psychiatric disorders according to the fifth edition of Diagnostic and Statistical Manual of Psychiatric Disorders treated with serotonin specific reuptake inhibitor or serotonin norepinephrine reuptake inhibitor in the age range of 18-50 year-old; Suffer from sexual dysfunction according to the fifth edition of Diagnostic and Statistical Manual of Psychiatric Disorders; Having a regular and satisfying sexual activity before taking the serotonin specific reuptake inhibitor or serotonin norepinephrine reuptake inhibitor; Enable in sexual function
- •Exclusion criteria: Having sexual dysfunction before serotonin specific reuptake inhibitor or serotonin norepinephrine reuptake inhibitor; History of substance use interfere with sexual function (eg, alcohol, drugs, drug abuse or dependence during the past twelve months or positive urine test for illicit drugs); Electroconvulsive therapy during the 6 past months; Suicidality(active suicide or homicide intent, or a suicide or homicide attempt in the preceding 6 months); Mental retardation; Pregnant or at risk of pregnancy; Cognitive disorders such as dementia, delirium, or amnesia, traumatic brain injury; Current significant unstable medical illness (such as unstable cardiac disease, hepatic or renal impairment, evidence or history of malignancy or any significant hematological, endocrine); Axis II psychiatric disorders; Family history of bipolar disorder; Concomitant use with other psychiatric drugs; Hypersensitivity to aripiprazole; Previous treatment with aripiprazole in the past year; History of neuroleptic malignant syndrome; Unwilling or unable, in the opinion of the Investigator, to comply with study instructions
排除标准
- 未提供
研究者
相似试验
已完成
4 期
Aripiprazole effect in the treatment of residual symptoms in patients with schizophreniaIRCT2017013032236N3Vice chancellor for research, Mazandaran University of Medical Sciences50
已完成
不适用
A research of efficacy and safety of aripiprazole treatment for the behavioral symptoms in subjects with pervasive developmental disordes.Pervasive Developmental DisordersJPRN-UMIN000006558Department of Neuropsychiatry, Faculty of Medical Sciences, University of Fukui50
尚未招募
4 期
Comparing the effects of two medications for antipsychotic related weight gain: can adding aripiprazole or naltrexone help?CTRI/2024/02/062617Madhurima Dhar
已完成
3 期
Effect of Aripiprazole and Risperidone in Improving Obsessive-compulsive symptoms in Bipolar patientsCondition 1: Obsessive-compulsive disorder. Condition 2: Bipolar disorder.Obsessive-compulsive disorderBipolar disorderIRCT20170716035117N1Kashan University of Medical Sciences60
招募中
3 期
Best Choice between aripiprazole and risperidone in methamphetamine psychosisMetamphetamin induced psychotic disorder.Other stimulant abuse with stimulant-induced psychotic disorderF15.15IRCT20220103053615N1niversity of social welfare and rehabilitation sciences64